Clinical trials: Nervous System Cancer
Brain and Central Nervous System Tumors
Immunotoxin Therapy in Treating Children With Progressive or Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma
RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be an effective treatment for glioblastoma multiforme and anaplastic astrocytoma.
- Trial name
- NCT00052624
- Testing
- transferrin-CRM107
- Where
- 2 sites in United States
- Sponsor
- Xenova Biomedix
Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed…
- Conditions
- Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer
- Trial name
- NCT06047379
- Testing
- NEO212 Oral Capsule, Ipilimumab, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 134 people
- Sponsor
- Neonc Technologies, Inc.
Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
The study is a prospective, randomized controlled phase III trial, to test the efficacy, safety and neurocognitive outcomes of advanced NSCLC patients, following stereotactic radiosurgery (SRS) for 1 inoperable brain metastasis…
- Trial name
- NCT02831959
- Testing
- NovoTTF-200M device, Best Standard of Care
- Where
- 128 sites in United States, Austria and 13 more
- Volunteers
- 298 people
- Sponsor
- NovoCure GmbH
Primary Brain Tumors, Metastatic Malignant Neoplasm to Brain
Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome (DM-CHOC-PEN) in Patients With Brain Tumors
DM-CHOC-PEN is a polychlorinated pyridine cholesteryl carbonate that has demonstrated antineoplastic activities in patients with advanced cancers - melanoma, lung, breast and glioblastoma multiforme (GBM) involving the CNS during…
- Trial name
- DM-CHOC-PEN (NCT02038218)
- Testing
- 4-Demethyl-4-cholestryloxycarbonylpenclomedine
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- DEKK-TEC, Inc.
Pain, Analgesics, Opioid
A Study of OROS Hydromorphone HCL vs Morphine in Cancer Pain Patients.
The purpose of this study was to demonstrate the clinical equivalence of hydromorphone and morphine (immediate-release [IR] and sustained-release [SR] formulations) using the "worst pain in the past 24 hours" item of the Brief…
- Trial name
- NCT00410540
- Testing
- OROS hydromorphone HCL ; Morphine sulfate
- Volunteers
- 202 people
- Sponsor
- Alza Corporation, DE, USA
Glioma
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
This is a multi-center, sequential cohort, open-label, volume and dose escalation study of the safety, tolerability, and distribution of 186RNL given by convection enhanced delivery to patients with recurrent or progressive…
- Trial name
- NCT01906385
- Testing
- Rhenium Liposome Treatment
- Where
- 4 sites in United States
- Volunteers
- 55 people
- Sponsor
- Cerenome
Neoplasm Metastasis, Brain Neoplasms
Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases
The primary purpose of the study is to evaluate if motexafin gadolinium with whole brain radiation therapy followed by a stereotactic radiosurgery boost is a safe and effective treatment.
- Trial name
- NCT00121420
- Testing
- Motexafin gadolinium
- Where
- 12 sites in United States, Canada
- Volunteers
- 45 people
- Sponsor
- Pharmacyclics LLC.
Neurofibromatosis
Clinical and Demographic Characteristics of Adult p Atients With NEurofibromatosis in RUSsia
Clinical and Demographic Characteristics of Adult Patients with NEurofibromatosis in RUSsia (NEREUS)
- Trial name
- NEREUS (NCT07088991)
- Where
- 16 sites in Russia
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Cancers, Pain
Efficacy and Safety Study of Nasalfent for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids
Cancer patients taking regular medication for their pain often still have episodes of severe pain that 'break through' despite their background pain treatment.
- Trial name
- NCT00589823
- Testing
- Fentanyl citrate, Immediate release morphine sulphate
- Where
- United Kingdom
- Volunteers
- 135 people
- Sponsor
- Archimedes Development Ltd
Solid Tumor, Adult, Brain Tumor, Primary
Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors
This is a first-in-human, open-label, multicenter, dose-escalation, safety, PK, and biomarker study of PBI-200 in subjects with NTRK-fusion-positive advanced or metastatic solid tumors.
- Conditions
- Solid Tumor, Adult, Brain Tumor, Primary, Desmoplastic Small Round Cell Tumor
- Trial name
- NCT04901806
- Testing
- PBI-200
- Where
- 42 sites in United States, Australia and 9 more
- Volunteers
- 29 people
- Sponsor
- Pyramid Biosciences
Refractory or Relapsed Solid Tumors, Lymphoma
Phase I/II Study of Avelumab in Pediatric Cancer Participants
This is a multi-center, open-label, international study to evaluate the dose, safety and tolerability, antitumor activity, pharmacokinetic and pharmacodynamics of avelumab in pediatric subjects 0 to less than 18 years of age with…
- Trial name
- NCT03451825
- Testing
- Avelumab
- Where
- 11 sites in United States, Belgium and 3 more
- Volunteers
- 21 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Neurofibromatosis 1, Neurofibroma Plexiform
A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
A Phase 1 Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of Selumetinib, a Selective Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor, in Chinese Paediatric and Adult Subjects…
- Trial name
- NCT04590235
- Testing
- Selumetinib
- Where
- 2 sites in China
- Volunteers
- 32 people
- Sponsor
- AstraZeneca
Brain Neoplasms, Malignant Neoplasms, Brain
Study of Karenitecin (BNP1350) in Patients With Brain Tumors
The purpose of this study is to evaluate safety and efficacy ofKarenitecin (BNP1350) as a treatment of adults with brain tumors.
- Conditions
- Brain Neoplasms, Malignant Neoplasms, Brain, Brain Tumors
- Trial name
- NCT00062478
- Testing
- Karenitecin (BNP1350)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- BioNumerik Pharmaceuticals, Inc.
Non Small Cell Lung Cancer (NSCLC)
A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC
This is a Phase I/II, Open Label Study of WSD0922-FU in Combination with Osimertinib for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose disease has progressed with third-generation EGFR-TKI with…
- Trial name
- WAYWIN103 (NCT07206498)
- Testing
- Osimertinib (Tagrisso®), WSD0922-FU
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Wayshine Biopharm, Inc.
Insomnia, Breast Cancer
PERSONAL - Sleep In Breast Cancer
Sleep is essential for human function, immunity, and well-being. In the general population, sleep disturbance and insomnia cause significant health problems and impact on the quality of life of many individuals.
- Trial name
- NCT05093426
- Testing
- Stage 2 Digital sleep diary app
- Where
- United Kingdom
- Volunteers
- 226 people
- Sponsor
- Closed Loop Medicine
Lymphoma
A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)
The purpose of this study is to determine whether Nivolumab is effective in the treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)
- Trial name
- CheckMate 647 (NCT02857426)
- Testing
- Nivolumab
- Where
- 50 sites in United States, Brazil and 11 more
- Volunteers
- 66 people
- Sponsor
- Bristol-Myers Squibb
Brain Metastases
Evaluation of Clinical Decision Support System for Brain Metastasis Using Brain MR Images
BT-M01 is a software that has been pre-learned based on a brain metastasis detection model using brain MR images, and clinical decision support system for brain metastasis by automatically analyzing brain MR images by assisting…
- Trial name
- NCT05573815
- Testing
- BT-M01
- Where
- South Korea
- Volunteers
- 558 people
- Sponsor
- Heuron Inc.
Advanced Non-Small Cell Lung Cancer With MET Mutations
CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC
This study will look at how effective the study drug (tepotinib) is at stopping the growth and spread of lung cancer with central nervous system metastasis.
- Trial name
- NCT04739358
- Testing
- Tepotinib
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- Criterium, Inc.
Cancer, Pain
Long-term Safety and Efficacy Study of Fentanyl Sublingual Spray for the Treatment of Breakthrough Cancer Pain
The purpose of this study was to assess the 90-day safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain in subjects on around-the-clock opioids for their persistent cancer pain.
- Trial name
- NCT00538863
- Testing
- Fentanyl sublingual spray
- Where
- 52 sites in United States, Canada and 1 more
- Volunteers
- 319 people
- Sponsor
- INSYS Therapeutics Inc
Pain
Comparison of Nasal Fentanyl and Oral Transmucosal Fentanyl (Actiq) in Cancer Breakthrough Pain (FT-019-IM)
Primary: To compare the efficacy of nasal fentanyl (NF) to oral transmucosal fentanyl (Actiq®) (hereafter Actiq) in the management of breakthrough pain in cancer patients.
- Trial name
- NCT00496392
- Testing
- Nasal fentanyl
- Where
- Denmark
- Volunteers
- 115 people
- Sponsor
- Nycomed